

Christoph Hiemke

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8531737/publications.pdf>

Version: 2024-02-01

398
papers

15,252
citations

23500

58
h-index

33814

99
g-index

430
all docs

430
docs citations

430
times ranked

11950
citing authors

#	ARTICLE	IF	CITATIONS
1	Consensus Guidelines for Therapeutic Drug Monitoring in Neuropsychopharmacology: Update 2017. <i>Pharmacopsychiatry</i> , 2018, 51, 9-62.	1.7	787
2	AGNP Consensus Guidelines for Therapeutic Drug Monitoring in Psychiatry: Update 2011. <i>Pharmacopsychiatry</i> , 2011, 44, 195-235.	1.7	774
3	Pharmacokinetics of selective serotonin reuptake inhibitors. , 2000, 85, 11-28.		666
4	A disintegrin-metalloproteinase prevents amyloid plaque formation and hippocampal defects in an Alzheimer disease mouse model. <i>Journal of Clinical Investigation</i> , 2004, 113, 1456-1464.	3.9	532
5	The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry. <i>Pharmacopsychiatry</i> , 2004, 37, 243-265.	1.7	453
6	Astroglial Plasticity in the Hippocampus is Affected by Chronic Psychosocial Stress and Concomitant Fluoxetine Treatment. <i>Neuropsychopharmacology</i> , 2006, 31, 1616-1626.	2.8	388
7	Chronic Social Stress Inhibits Cell Proliferation in the Adult Medial Prefrontal Cortex: Hemispheric Asymmetry and Reversal by Fluoxetine Treatment. <i>Neuropsychopharmacology</i> , 2007, 32, 1490-1503.	2.8	314
8	CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2006, 31, 493-502.	0.7	212
9	Melperone is an Inhibitor of the CYP2D6 Catalyzed O-demethylation of Venlafaxine. <i>Pharmacopsychiatry</i> , 2003, 36, 3-6.	1.7	154
10	Psychosocial stress in tree shrews: Clomipramine counteracts behavioral and endocrine changes. <i>Pharmacology Biochemistry and Behavior</i> , 1996, 54, 219-228.	1.3	150
11	Strain Differences in Open-Field and Elevated Plus-Maze Behavior of Rats Without and With Pretest Handling. <i>Pharmacology Biochemistry and Behavior</i> , 1998, 59, 807-811.	1.3	144
12	Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 329-36.	0.8	143
13	Kavapyrone enriched extract from <i>Piper methysticum</i> as modulator of the GABA binding site in different regions of rat brain. <i>Psychopharmacology</i> , 1994, 116, 469-474.	1.5	140
14	Elevated Levels of Clozapine in Serum After Addition of Fluvoxamine. <i>Journal of Clinical Psychopharmacology</i> , 1994, 14, 279-280.	0.7	140
15	Brain and Plasma Pharmacokinetics of Aripiprazole in Patients With Schizophrenia: An [¹⁸ F]Fallypride PET Study. <i>American Journal of Psychiatry</i> , 2008, 165, 988-995.	4.0	139
16	Pharmacokinetic Interactions of Clozapine With Selective Serotonin Reuptake Inhibitors. <i>Journal of Clinical Psychopharmacology</i> , 1998, 18, 2-9.	0.7	138
17	Identification of P-glycoprotein substrates and inhibitors among psychoactive compounds – implications for pharmacokinetics of selected substrates. <i>Journal of Pharmacy and Pharmacology</i> , 2010, 56, 967-975.	1.2	126
18	Pregabalin abuse and dependence in Germany: results from a database query. <i>European Journal of Clinical Pharmacology</i> , 2013, 69, 1335-1342.	0.8	109

#	ARTICLE	IF	CITATIONS
19	Effects of fluoxetine on behavioral deficits evoked by chronic social stress in rats. Behavioural Brain Research, 2006, 174, 188-192.	1.2	107
20	Increased CSF APPs- β levels in patients with Alzheimer disease treated with acitretin. Neurology, 2014, 83, 1930-1935.	1.5	107
21	An International Adult Guideline for Making Clozapine Titration Safer by Using Six Ancestry-Based Personalized Dosing Titrations, CRP, and Clozapine Levels. Pharmacopsychiatry, 2022, 55, 73-86.	1.7	107
22	Therapeutic Monitoring of New Antipsychotic Drugs. Therapeutic Drug Monitoring, 2004, 26, 156-160.	1.0	105
23	TDM in psychiatry and neurology: A comprehensive summary of the consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology, update 2017; a tool for clinicians. World Journal of Biological Psychiatry, 2018, 19, 162-174.	1.3	103
24	Citalopram counteracts depressive-like symptoms evoked by chronic social stress in rats. Behavioural Pharmacology, 2006, 17, 19-29.	0.8	102
25	Serum levels of aripiprazole and dehydroaripiprazole, clinical response and side effects. World Journal of Biological Psychiatry, 2008, 9, 212-218.	1.3	97
26	The Striatal and Extrastriatal D2/D3 Receptor-Binding Profile of Clozapine in Patients with Schizophrenia. Neuropsychopharmacology, 2006, 31, 1027-1035.	2.8	96
27	Increased bioavailability of oral melatonin after fluvoxamine coadministration*1. Clinical Pharmacology and Therapeutics, 2000, 67, 1-6.	2.3	94
28	Pharmacological validation of a chronic social stress model of depression in rats: effects of reboxetine, haloperidol and diazepam. Behavioural Pharmacology, 2008, 19, 183-196.	0.8	93
29	The Chronic Psychosocial Stress Paradigm in Male Tree Shrews: Evaluation of a Novel Animal Model for Depressive Disorders. Stress, 2002, 5, 37-46.	0.8	88
30	Chronic psychosocial stress and citalopram modulate the expression of the glial proteins GFAP and NDRG2 in the hippocampus. Psychopharmacology, 2012, 224, 209-222.	1.5	88
31	Blood Levels to Optimize Antipsychotic Treatment in Clinical Practice. Journal of Clinical Psychiatry, 2020, 81, .	1.1	86
32	Assessing drug-drug interactions through therapeutic drug monitoring when administering oral second-generation antipsychotics. Expert Opinion on Drug Metabolism and Toxicology, 2016, 12, 407-422.	1.5	82
33	Combination of open field and elevated plus-maze: A suitable test battery to assess strain as well as treatment differences in rat behavior. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1998, 22, 1197-1215.	2.5	78
34	Addition of Low-Dose Fluvoxamine to Low-Dose Clozapine Monotherapy in Schizophrenia: Drug Monitoring and Tolerability Data from a Prospective Clinical Trial. Pharmacopsychiatry, 1999, 32, 148-153.	1.7	76
35	The HTR1B 861G>C receptor polymorphism among patients suffering from alcoholism, major depression, anxiety disorders and narcolepsy. Psychiatry Research, 2000, 97, 1-10.	1.7	74
36	Differential Effects of Fluvoxamine and Other Antidepressants on the Biotransformation of Melatonin. Journal of Clinical Psychopharmacology, 2001, 21, 167-174.	0.7	74

#	ARTICLE	IF	CITATIONS
37	Effects of Pulsed High-Frequency Electromagnetic Fields on the Neuroendocrine System. <i>Neuroendocrinology</i> , 1998, 67, 139-144.	1.2	72
38	Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. <i>Neuroscience Letters</i> , 2002, 330, 231-234.	1.0	72
39	Determination of clozapine and its major metabolites in human serum using automated solid-phase extraction and subsequent isocratic high-performance liquid chromatography with ultraviolet detection. <i>Biomedical Applications</i> , 1992, 583, 209-216.	1.7	71
40	Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients. <i>Psychopharmacology</i> , 1993, 110, 302-308.	1.5	71
41	Expression of alpha subunit genes of nicotinic acetylcholine receptors in human lymphocytes. <i>Neuroscience Letters</i> , 1996, 214, 171-174.	1.0	70
42	Chronic psychosocial stress and antidepressant treatment in tree shrews: time-dependent behavioral and endocrine effects. <i>Neuroscience and Biobehavioral Reviews</i> , 1999, 23, 937-947.	2.9	69
43	Automated analysis of quetiapine and other antipsychotic drugs in human blood by high performance-liquid chromatography with column-switching and spectrophotometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2006, 830, 342-348.	1.2	69
44	Inflammation and psychotropic drugs: the relationship between C-reactive protein and antipsychotic drug levels. <i>Psychopharmacology</i> , 2016, 233, 1695-1705.	1.5	69
45	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone. <i>Expert Review of Clinical Pharmacology</i> , 2017, 10, 965-981.	1.3	69
46	A comprehensive review of the clinical utility of and a combined analysis of the clozapine/norclozapine ratio in therapeutic drug monitoring for adult patients. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 603-621.	1.3	69
47	Fluvoxamine But Not Sertraline Inhibits the Metabolism of Olanzapine: Evidence From A Therapeutic Drug Monitoring Service. <i>Therapeutic Drug Monitoring</i> , 2001, 23, 410-413.	1.0	68
48	Nocturnal hormone profiles in patients with schizophrenia treated with olanzapine. <i>Psychoneuroendocrinology</i> , 2006, 31, 256-264.	1.3	68
49	Therapeutic Monitoring of Aripiprazole by HPLC with Column-Switching and Spectrophotometric Detection. <i>Clinical Chemistry</i> , 2005, 51, 1718-1721.	1.5	67
50	The early non-increase of serum BDNF predicts failure of antidepressant treatment in patients with major depression: A pilot study. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2011, 35, 415-420.	2.5	67
51	Neuroendocrine response to antipsychotics: effects of drug type and gender. <i>Biological Psychiatry</i> , 1999, 45, 89-97.	0.7	66
52	Therapeutic Drug Monitoring of Tricyclic Antidepressants: How Does it Work under Clinical Conditions?. <i>Pharmacopsychiatry</i> , 2003, 36, 98-104.	1.7	66
53	Cognitive Behavioral Therapy Versus Sertraline in Patients With Depression and Poorly Controlled Diabetes: The Diabetes and Depression (DAD) Study. <i>Diabetes Care</i> , 2015, 38, 767-775.	4.3	66
54	Effect of chronic citalopram on serotonin-related and stress-regulated genes in the dorsal raphe nucleus of the rat. <i>European Neuropsychopharmacology</i> , 2007, 17, 417-429.	0.3	62

#	ARTICLE	IF	CITATIONS
55	Early reactions of brain-derived neurotrophic factor in plasma (pBDNF) and outcome to acute antidepressant treatment in patients with Major Depression. <i>Neuropharmacology</i> , 2012, 62, 264-269.	2.0	62
56	Fluvoxamine Augmentation of Olanzapine in Chronic Schizophrenia: Pharmacokinetic Interactions and Clinical Effects. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 502-506.	0.7	61
57	Determination of citalopram and escitalopram together with their active main metabolites desmethyl(es)-citalopram in human serum by column-switching high performance liquid chromatography (HPLC) and spectrophotometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 848, 391-394.	1.2	60
58	Nonlinear Pharmacokinetics of Fluvoxamine and Gender Differences. <i>Therapeutic Drug Monitoring</i> , 1998, 20, 446-449.	1.0	60
59	AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. <i>Pharmacopsychiatry</i> , 2011, 44, 195-235.	1.7	59
60	Automated Determination of Fluvoxamine in Plasma by Column-Switching High-Performance Liquid Chromatography. <i>Clinical Chemistry</i> , 1992, 38, 2082-2086.	1.5	57
61	Simultaneous determination of olanzapine, clozapine and demethylated metabolites in serum by on-line column-switching high-performance liquid chromatography. <i>Biomedical Applications</i> , 2001, 759, 63-71.	1.7	57
62	Distribution of clozapine and desmethylclozapine between blood and brain in rats. <i>European Neuropsychopharmacology</i> , 1999, 9, 253-256.	0.3	56
63	Pharmacogenomics in Psychiatry: From Therapeutic Drug Monitoring to Genomic Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 95, 254-257.	2.3	56
64	Acute antagonism of dopamine D2-like receptors by amisulpride: Effects on hormone secretion in healthy volunteers. <i>Journal of Psychiatric Research</i> , 1994, 28, 461-473.	1.5	55
65	Clinical utility of drug measurement and pharmacokinetics " therapeutic drug monitoring in psychiatry. <i>European Journal of Clinical Pharmacology</i> , 2008, 64, 159-166.	0.8	55
66	Pharmacodynamic consequences of P-glycoprotein-dependent pharmacokinetics of risperidone and haloperidol in mice. <i>Behavioural Brain Research</i> , 2008, 188, 298-303.	1.2	52
67	Safety of psychotropic medications in people with COVID-19: evidence review and practical recommendations. <i>BMC Medicine</i> , 2020, 18, 215.	2.3	52
68	Inhibition of synaptosomal high-affinity uptake of dopamine and serotonin by estrogen agonists and antagonists. <i>Biochemical Pharmacology</i> , 1987, 36, 3175-3180.	2.0	51
69	Cyclosporine A (CsA) affects the pharmacodynamics and pharmacokinetics of the atypical antipsychotic amisulpride probably via inhibition of P-glycoprotein (P-gp). <i>Journal of Neural Transmission</i> , 2006, 113, 787-801.	1.4	51
70	Therapeutic drug monitoring for optimizing amisulpride therapy in patients with Schizophrenia. <i>Journal of Psychiatric Research</i> , 2007, 41, 673-679.	1.5	51
71	Improved Efficacy and Fewer Side Effects Under Clozapine Treatment After Addition of Fluvoxamine. <i>Journal of Clinical Psychopharmacology</i> , 1995, 15, 141-143.	0.7	51
72	High striatal occupancy of D2-like dopamine receptors by amisulpride in the brain of patients with schizophrenia. <i>International Journal of Neuropsychopharmacology</i> , 2004, 7, 421-430.	1.0	50

#	ARTICLE	IF	CITATIONS
73	The AGNP-TDM Expert Group Consensus Guidelines: focus on therapeutic monitoring of antidepressants. <i>Dialogues in Clinical Neuroscience</i> , 2005, 7, 231-247.	1.8	50
74	Appropriateness of Therapeutic Drug Monitoring for Antidepressants in Routine Psychiatric Inpatient Care. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 83-88.	1.0	49
75	Clinical improvement in a case of frontotemporal dementia under aripiprazole treatment corresponds to partial recovery of disturbed frontal glucose metabolism. <i>World Journal of Biological Psychiatry</i> , 2007, 8, 123-126.	1.3	49
76	Therapeutic Drug Monitoring for Antidepressant Drug Treatment. <i>Current Pharmaceutical Design</i> , 2012, 18, 5818-5827.	0.9	49
77	Coadministration of Clozapine and Fluvoxamine in Psychotic Patients - Clinical Experience. <i>Pharmacopsychiatry</i> , 1999, 32, 76-77.	1.7	48
78	Therapeutic Plasma Concentrations of Antidepressants and Antipsychotics: Lessons from PET Imaging. <i>Pharmacopsychiatry</i> , 2011, 44, 236-248.	1.7	48
79	Evaluation of naltrexone for dissociative symptoms in borderline personality disorder. <i>International Clinical Psychopharmacology</i> , 2012, 27, 61-68.	0.9	48
80	Diazepam Has No Beneficial Effects on Stress-Induced Behavioural and Endocrine Changes in Male Tree Shrews. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 65, 539-546.	1.3	47
81	Serotonergic polymorphisms in patients suffering from alcoholism, anxiety disorders and narcolepsy. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 965-982.	2.5	46
82	Therapeutic drug monitoring in neuropsychopharmacology: does it hold its promises?. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2008, 258, 21-27.	1.8	45
83	Toxic Clozapine Serum Levels During Inflammatory Reactions. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 392-394.	0.7	45
84	CYP2D6 genotype and phenotyping by determination of dextromethorphan and metabolites in serum of healthy controls and of patients under psychotropic medication. <i>Pharmacogenetics and Genomics</i> , 1997, 7, 453-461.	5.7	43
85	Over-expression of two different forms of the β -secretase ADAM10 affects learning and memory in mice. <i>Behavioural Brain Research</i> , 2006, 175, 278-284.	1.2	43
86	Serum concentrations of paliperidone versus risperidone and clinical effects. <i>European Journal of Clinical Pharmacology</i> , 2010, 66, 797-803.	0.8	43
87	Automated determination of amisulpride by liquid chromatography with column switching and spectrophotometric detection. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 784, 405-410.	1.2	42
88	Therapeutic Monitoring of Psychotropic Drugs. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 167-170.	1.0	42
89	Effects of escitalopram on the regulation of brain-derived neurotrophic factor and nerve growth factor protein levels in a rat model of chronic stress. <i>Journal of Neuroscience Research</i> , 2009, 87, 2551-2560.	1.3	42
90	Pharmacokinetics of acute and sub-chronic aripiprazole in P-glycoprotein deficient mice. <i>Neuropharmacology</i> , 2010, 59, 474-479.	2.0	41

#	ARTICLE	IF	CITATIONS
91	Serotonin Syndrome as a Result of Fluoxetine in a Patient With Tramadol Abuse: Plasma Level-correlated Symptomatology. <i>Journal of Clinical Psychopharmacology</i> , 2002, 22, 440-441.	0.7	41
92	Interferon-Alpha-2-Induced Stimulation of ACTH and Cortisol Secretion in Man. <i>Neuroendocrinology</i> , 1991, 54, 499-503.	1.2	40
93	Aripiprazole in Pregnancy and Lactation. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 204-205.	0.7	40
94	Acitretin, an Enhancer of Alpha-Secretase Expression, Crosses the Blood-Brain Barrier and Is Not Eliminated by P-Glycoprotein. <i>Neurodegenerative Diseases</i> , 2012, 10, 224-228.	0.8	40
95	Desomorphine Goes "Crocodile", <i>Journal of Addictive Diseases</i> , 2012, 31, 407-412.	0.8	40
96	Concentration"Effect Relationships of Psychoactive Drugs and the Problem to Calculate Therapeutic Reference Ranges. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 174-179.	1.0	40
97	Column switching and high-performance liquid chromatography in the analysis of amitriptyline, nortriptyline and hydroxylated metabolites in human plasma or serum. <i>Biomedical Applications</i> , 1992, 578, 273-282.	1.7	39
98	Automated Determination of Paroxetine and Its Main Metabolite by Column Switching and On-Line High-Performance Liquid Chromatography. <i>Therapeutic Drug Monitoring</i> , 1994, 16, 400-406.	1.0	39
99	Automated determination of reboxetine by high-performance liquid chromatography with column-switching and ultraviolet detection. <i>Biomedical Applications</i> , 2000, 740, 135-140.	1.7	39
100	How Does the Benzamide Antipsychotic Amisulpride get into the Brain?"An In Vitro Approach Comparing Amisulpride with Clozapine. <i>Neuropsychopharmacology</i> , 2003, 28, 1916-1922.	2.8	39
101	Assessment of Storage and Transport Stability of New Antidepressant and Antipsychotic Drugs for a Nationwide TDM Service. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 459-461.	1.0	39
102	Blood"brain barrier penetration of the enantiomers of venlafaxine and its metabolites in mice lacking P-glycoprotein. <i>European Neuropsychopharmacology</i> , 2010, 20, 632-640.	0.3	39
103	Elevated levels of clozapine in serum after addition of fluvoxamine. <i>Journal of Clinical Psychopharmacology</i> , 1994, 14, 279-81.	0.7	39
104	Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. <i>Behavioural Pharmacology</i> , 1999, 10, 131-137.	0.8	38
105	Genetic polymorphisms of the dopamine D2 and D3 receptor and neuroleptic drug effects in schizophrenic patients. <i>Schizophrenia Research</i> , 2001, 49, 223-225.	1.1	38
106	Striatal and Extrastriatal D2/D3-Receptor-Binding Properties of Ziprasidone. <i>Journal of Clinical Psychopharmacology</i> , 2008, 28, 608-617.	0.7	38
107	Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression "The EMC trial. <i>European Neuropsychopharmacology</i> , 2016, 26, 705-716.	0.3	38
108	Stimulation of immediate early gene expression by desipramine in rat brain. <i>Biological Psychiatry</i> , 1997, 42, 317-323.	0.7	37

#	ARTICLE	IF	CITATIONS
109	Reduction Of Clozapine-Induced Hypersalivation By Pirenzepine Is Safe. <i>Pharmacopsychiatry</i> , 2004, 37, 43-45.	1.7	37
110	A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 1237-1253.	1.3	37
111	Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. <i>Journal of Clinical Psychiatry</i> , 1996, 57, 257-64.	1.1	37
112	Quantification of D2-like dopamine receptors in the human brain with 18F-desmethoxyfallypride. <i>Journal of Nuclear Medicine</i> , 2003, 44, 109-16.	2.8	37
113	Competition by monophenolic estrogens and catecholestrogens for high-affinity uptake of [3H](α)-norepinephrine into synaptosomes from rat cerebral cortex and hypothalamus. <i>Brain Research</i> , 1983, 277, 163-168.	1.1	36
114	Interaction of non-steroidal antiestrogens with dopamine receptor binding. <i>The Journal of Steroid Biochemistry</i> , 1984, 21, 663-667.	1.3	36
115	Anxiolytic-like effects of acute and chronic GABA transporter inhibition in rats. <i>Journal of Neural Transmission</i> , 2002, 109, 871-880.	1.4	36
116	Population pharmacokinetic analysis of mirtazapine. <i>European Journal of Clinical Pharmacology</i> , 2004, 60, 473-480.	0.8	34
117	Chronic Lithium Salt Treatment Reduces CRE/CREB-Directed Gene Transcription and Reverses Its Upregulation by Chronic Psychosocial Stress in Transgenic Reporter Gene Mice. <i>Neuropsychopharmacology</i> , 2008, 33, 2407-2415.	2.8	34
118	Altered brain concentrations of citalopram and escitalopram in P-glycoprotein deficient mice after acute and chronic treatment. <i>European Neuropsychopharmacology</i> , 2013, 23, 1636-1644.	0.3	34
119	A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 625-639.	1.3	34
120	Dopamine D2/3 receptor occupancy by quetiapine in striatal and extrastriatal areas. <i>International Journal of Neuropsychopharmacology</i> , 2010, 13, 951-960.	1.0	33
121	Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 281-286.	0.7	33
122	Sub-acute effects of interferon- γ on adrenocorticotrophic hormone, cortisol, growth hormone and prolactin in humans. <i>Psychoneuroendocrinology</i> , 1992, 17, 459-465.	1.3	32
123	Automated determination of clomipramine and its major metabolites in human and rat serum by high-performance liquid chromatography with on-line column-switching. <i>Biomedical Applications</i> , 1998, 710, 227-233.	1.7	32
124	Sex differences in allelic frequencies of the 5-HT _{2C} Cys23Ser polymorphism in psychiatric patients and healthy volunteers: findings from an association study. <i>Psychiatric Genetics</i> , 2000, 10, 59-65.	0.6	32
125	Relationship between Mirtazapine Dose, Plasma Concentration, Response, and Side Effects in Clinical Practice. <i>Pharmacopsychiatry</i> , 2005, 38, 113-117.	1.7	32
126	The Effect of Age, Sex, Smoking and Co-Medication on Serum Levels of Venlafaxine and O-Desmethylvenlafaxine under Naturalistic Conditions. <i>Pharmacopsychiatry</i> , 2012, 45, 229-235.	1.7	32

#	ARTICLE	IF	CITATIONS
127	Circadian variations in antigen-specific proliferation of human T lymphocytes and correlation to cortisol production. <i>Psychoneuroendocrinology</i> , 1995, 20, 335-342.	1.3	31
128	Steady state concentrations of clomipramine and its major metabolite desmethylclomipramine in rat brain and serum after oral administration of clomipramine. <i>European Neuropsychopharmacology</i> , 2000, 10, 401-405.	0.3	31
129	Tiagabine, a $\hat{1}^3$ -amino-butyric acid transporter inhibitor impairs spatial learning of rats in the Morris water-maze. <i>Behavioural Brain Research</i> , 2002, 133, 391-394.	1.2	31
130	HPMA Based Amphiphilic Copolymers Mediate Central Nervous Effects of Domperidone. <i>Macromolecular Rapid Communications</i> , 2011, 32, 712-717.	2.0	31
131	Non-Fatal and Fatal Liver Failure Associated with Valproic Acid. <i>Pharmacopsychiatry</i> , 2013, 46, 63-68.	1.7	31
132	Abuse of methylphenidate in Germany: Data from spontaneous reports of adverse drug reactions. <i>Psychiatry Research</i> , 2014, 215, 252-254.	1.7	31
133	Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone; A pharmacokinetics-based hypothesis. <i>Psychoneuroendocrinology</i> , 2016, 73, 9-15.	1.3	31
134	Increase in Serum Clomipramine Concentrations Caused by Valproate. <i>Journal of Clinical Psychopharmacology</i> , 2000, 20, 493-494.	0.7	31
135	Automated Determination of Dextromethorphan and Its Main Metabolites in Human Plasma by High-Performance Liquid Chromatography and Column Switching. <i>Therapeutic Drug Monitoring</i> , 1996, 18, 297-303.	1.0	31
136	Prolactin plasma levels and D2-dopamine receptor occupancy measured with IBZM-SPECT. <i>Psychopharmacology</i> , 1996, 124, 285-287.	1.5	30
137	Fishing for a drug: solid-phase microextraction for the assay of clozapine in human plasma. <i>Biomedical Applications</i> , 1999, 731, 231-240.	1.7	30
138	Long-Term Effects of the Substituted Benzamide Derivative Amisulpride on Baseline and Stimulated Prolactin Levels. <i>Neuropsychobiology</i> , 2002, 46, 33-40.	0.9	30
139	Large Variability of Aripiprazole and Dehydroaripiprazole Serum Concentrations in Adolescent Patients with Schizophrenia. <i>Therapeutic Drug Monitoring</i> , 2008, 30, 462-466.	1.0	30
140	Gender Aspects in the Clinical Treatment of Schizophrenic Inpatients With Amisulpride: A Therapeutic Drug Monitoring Study. <i>Pharmacopsychiatry</i> , 2006, 39, 41-46.	1.7	29
141	Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived from Spontaneous Reports of Adverse Drug Reactions. <i>Pharmacopsychiatry</i> , 2013, 46, 214-220.	1.7	29
142	Potential Cost-effectiveness of Therapeutic Drug Monitoring for Depressed Patients Treated With Citalopram. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 396-401.	1.0	29
143	Serum Concentrations of Hydroxybupropion for Dose Optimization of Depressed Patients Treated With Bupropion. <i>Therapeutic Drug Monitoring</i> , 2014, 36, 473-479.	1.0	29
144	Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. <i>Clinical Chemistry</i> , 1994, 40, 1778-1779.	1.5	28

#	ARTICLE	IF	CITATIONS
145	Therapeutic Drug Monitoring of the Antidepressant Mirtazapine and Its N-Demethylated Metabolite in Human Serum. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 78-84.	1.0	28
146	Paroxetine Serum Concentrations in Depressed Patients and Response to Treatment. <i>Pharmacopsychiatry</i> , 2005, 38, 118-121.	1.7	28
147	Duloxetine Serum Concentrations and Clinical Effects. Data from a Therapeutic Drug Monitoring (TDM) Survey. <i>Pharmacopsychiatry</i> , 2009, 42, 189-193.	1.7	28
148	Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with Major Depressive Disorder - the EMC trial. <i>Trials</i> , 2010, 11, 21.	0.7	28
149	Pharmacokinetic Drug-Drug Interactions of Mood Stabilizers and Risperidone in Patients Under Combined Treatment. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 554-561.	0.7	28
150	Effects of antipsychotic treatment on cognition in healthy subjects. <i>Journal of Psychopharmacology</i> , 2013, 27, 374-385.	2.0	27
151	Chronic Oral Haloperidol and Clozapine in Rats: A Behavioral Evaluation. <i>Neuropsychobiology</i> , 1999, 39, 86-91.	0.9	26
152	The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. <i>Pharmaceutical Research</i> , 2002, 19, 1034-1037.	1.7	26
153	Hormonal Influences on Cardiovascular Norepinephrine Transporter Responses in Healthy Women. <i>Hypertension</i> , 2008, 51, 1203-1209.	1.3	26
154	In vitro P-glycoprotein efflux inhibition by atypical antipsychotics is in vivo nicely reflected by pharmacodynamic but less by pharmacokinetic changes. <i>Pharmacology Biochemistry and Behavior</i> , 2012, 102, 312-320.	1.3	26
155	Steady-state serum concentrations of venlafaxine in patients with late-life depression. Impact of age, sex and BMI. <i>Journal of Neural Transmission</i> , 2015, 122, 721-729.	1.4	26
156	Sex differences in GABAA receptor binding in rat brain measured by an improved in vitro binding assay. <i>Experimental Brain Research</i> , 1990, 81, 297-302.	0.7	25
157	Effects of ovariectomy and steroid replacement on GABAA receptor binding in female rat brain. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1991, 38, 141-147.	1.2	25
158	Fluvoxamine or Placebo in the Treatment of Panic Disorder and Relationship to Blood Concentrations of Fluvoxamine. <i>Pharmacopsychiatry</i> , 1998, 31, 117-121.	1.7	25
159	Therapeutic Drug Monitoring for Drugs Used in the Treatment of Substance-Related Disorders: Literature Review Using a Therapeutic Drug Monitoring Appropriateness Rating Scale. <i>Therapeutic Drug Monitoring</i> , 2011, 33, 561-572.	1.0	25
160	Pharmacokinetic patterns of risperidone-associated adverse drug reactions. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 1091-1098.	0.8	25
161	Consensus Guideline Based Therapeutic Drug Monitoring (TDM) in Psychiatry and Neurology. <i>Current Drug Delivery</i> , 2016, 13, 353-361.	0.8	25
162	Therapeutic Drug Monitoring in Italian Psychiatry. <i>Pharmacopsychiatry</i> , 2011, 44, 259-262.	1.7	24

#	ARTICLE	IF	CITATIONS
163	Automated Determination of Clozapine and Major Metabolites in Serum and Urine. <i>Therapeutic Drug Monitoring</i> , 1997, 19, 480-488.	1.0	24
164	Inhibition of dextromethorphan metabolism by moclobemide. <i>Psychopharmacology</i> , 1998, 135, 22-26.	1.5	23
165	Serum Concentrations of Fluvoxamine and Clinical Effects: A prospective open clinical trial. <i>Pharmacopsychiatry</i> , 1998, 31, 199-200.	1.7	23
166	Measurement of Duloxetine in Blood Using High-performance Liquid Chromatography with Spectrophotometric Detection and Column Switching. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 767-772.	1.0	23
167	Rotarod Impairment: Catalepsy-Like Screening Test for Antipsychotic Side Effects. <i>International Journal of Neuroscience</i> , 2009, 119, 1509-1522.	0.8	23
168	Amisulpride doses and plasma levels in different age groups of patients with schizophrenia or schizoaffective disorder. <i>Journal of Psychopharmacology</i> , 2009, 23, 278-286.	2.0	23
169	Effects on enantiomeric drug disposition and open-field behavior after chronic treatment with venlafaxine in the P-glycoprotein knockout mice model. <i>Psychopharmacology</i> , 2011, 215, 367-377.	1.5	23
170	Phenotyping and Genotyping of Drug Metabolism to Guide Pharmacotherapy in Psychiatry. <i>Current Drug Delivery</i> , 2013, 10, 46-53.	0.8	23
171	Side effects related to potentially inappropriate medications in elderly psychiatric patients under everyday pharmacotherapy. <i>European Journal of Clinical Pharmacology</i> , 2015, 71, 165-172.	0.8	23
172	Therapeutic Drug Monitoring of Long-Acting Injectable Antipsychotic Drugs. <i>Therapeutic Drug Monitoring</i> , 2021, 43, 79-102.	1.0	23
173	Gas-liquid chromatographic properties of catecholamines, phenylethylamines and indolalkylamines as their propionyl derivatives. <i>Journal of Chromatography A</i> , 1978, 153, 451-460.	1.8	22
174	Time course of the effects of steroid hormone deprivation elicited by ovariectomy or ovariectomy plus adrenalectomy on the affinity and density of GABA binding sites in distinct rat brain areas. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1995, 103, 196-204.	0.6	22
175	Free-Choice Ethanol Consumption Under the Influence of GABAergic Drugs in Rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 457-462.	1.4	22
176	Automated Determination of Ziprasidone by HPLC With Column Switching and Spectrophotometric Detection. <i>Therapeutic Drug Monitoring</i> , 2005, 27, 158-162.	1.0	22
177	Tyrosine hydroxylase Val-81-Met polymorphism associated with early-onset alcoholism. <i>Psychiatric Genetics</i> , 2005, 15, 13-16.	0.6	22
178	Region specific distribution of levomepromazine in the human brain. <i>Journal of Neural Transmission</i> , 2006, 113, 387-397.	1.4	22
179	A common mechanism of action of the selective serotonin reuptake inhibitors citalopram and fluoxetine: Reversal of chronic psychosocial stress-induced increase in CRE/CREB-directed gene transcription in transgenic reporter gene mice. <i>European Journal of Pharmacology</i> , 2010, 633, 33-38.	1.7	22
180	Elevated risperidone serum concentrations during acute inflammation, two cases. <i>International Journal of Psychiatry in Medicine</i> , 2015, 50, 335-344.	0.8	22

#	ARTICLE	IF	CITATIONS
181	Pharmacokinetics of risperidone in different application forms – Comparing long-acting injectable and oral formulations. <i>European Neuropsychopharmacology</i> , 2018, 28, 130-137.	0.3	22
182	The role of cytochrome P450 2D6 in the metabolism of moclobemide. <i>European Neuropsychopharmacology</i> , 1996, 6, 225-230.	0.3	21
183	Effects of subchronic paroxetine administration on night-time endocrinological profiles in healthy male volunteers. <i>Psychoneuroendocrinology</i> , 2000, 25, 377-388.	1.3	21
184	Value and Actuality of the Prescription Information for Therapeutic Drug Monitoring of Psychopharmaceuticals: A Comparison with the Medico-Scientific Evidence. <i>Pharmacopsychiatry</i> , 2007, 40, 121-127.	1.7	21
185	LC with Column-Switching and Spectrophotometric Detection for Determination of Risperidone and 9-Hydroxyrisperidone in Human Serum. <i>Chromatographia</i> , 2008, 67, 321-324.	0.7	21
186	Differential effects of escitalopram on attention: a placebo-controlled, double-blind cross-over study. <i>Psychopharmacology</i> , 2009, 207, 213-223.	1.5	21
187	The value of drug and metabolite concentration in blood as a biomarker of psychopharmacological therapy. <i>International Review of Psychiatry</i> , 2013, 25, 494-508.	1.4	21
188	Therapeutic Drug Monitoring for Patients With Alzheimer Dementia to Improve Treatment With Donepezil. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 353-361.	1.0	21
189	Effect of smoking on risperidone pharmacokinetics – A multifactorial approach to better predict the influence on drug metabolism. <i>Schizophrenia Research</i> , 2017, 185, 51-57.	1.1	21
190	Effects of oestradiol benzoate and progesterone on luteinizing hormone release and catecholamine turnover in the preoptic-hypothalamic brain area of ovariectomized rats. <i>Journal of Endocrinology</i> , 1983, 97, 437-445.	1.2	20
191	Serotonergic modulation of response inhibition and re-engagement? Results of a study in healthy human volunteers. <i>Human Psychopharmacology</i> , 2010, 25, 472-480.	0.7	20
192	“Krokodil” Revival of an Old Drug with New Problems. <i>Substance Use and Misuse</i> , 2012, 47, 861-863.	0.7	20
193	Early Improvement and Serum Concentrations of Citalopram to Predict Antidepressant Drug Response of Patients with Major Depression. <i>Pharmacopsychiatry</i> , 2013, 46, 261-266.	1.7	20
194	Risperidone-induced extrapyramidal side effects. <i>International Clinical Psychopharmacology</i> , 2016, 31, 259-264.	0.9	20
195	Polypharmacy and the risk of drug-drug interactions and potentially inappropriate medications in hospital psychiatry. <i>Pharmacoepidemiology and Drug Safety</i> , 2021, 30, 1258-1268.	0.9	20
196	Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation. <i>Clinical Pharmacokinetics</i> , 2021, 60, 329-335.	1.6	20
197	Induction of c-fos gene expression by the selective sigma receptor ligand EMD 57445 in rat brain. <i>European Neuropsychopharmacology</i> , 1996, 6, 237-243.	0.3	19
198	Monitoring Serum Concentrations of Clomipramine and Metabolites: Fluorescence Polarization Immunoassay Versus High Performance Liquid Chromatography. <i>Pharmacopsychiatry</i> , 1997, 30, 128-132.	1.7	19

#	ARTICLE	IF	CITATIONS
199	Appropriateness of Plasma Level Determinations for Lithium and Valproate in Routine Care of Psychiatric Inpatients With Affective Disorders. <i>Journal of Clinical Psychopharmacology</i> , 2006, 26, 671-673.	0.7	19
200	Aripiprazole in human milk. <i>International Journal of Neuropsychopharmacology</i> , 2007, 10, 433.	1.0	19
201	The Serotonin Transporter Promoter Polymorphism (5-HTTLPR) Affects the Relation between Antidepressant Serum Concentrations and Effectiveness in Major Depression. <i>Pharmacopsychiatry</i> , 2012, 45, 108-113.	1.7	19
202	Interactions and Monitoring of Antipsychotic Drugs. <i>Handbook of Experimental Pharmacology</i> , 2012, , 241-265.	0.9	19
203	Sex-specific effects of estradiol on hypothalamic noradrenaline turnover in gonadectomized rats. <i>Experimental Brain Research</i> , 1985, 59, 68-72.	0.7	18
204	Haloperidol and risperidone have specific effects on altered pain sensitivity in the ketamine model of schizophrenia. <i>Psychopharmacology</i> , 2009, 202, 579-587.	1.5	18
205	High Mirtazapine Plasma Levels in Infant After Breast Feeding. <i>Journal of Clinical Psychopharmacology</i> , 2009, 29, 191-192.	0.7	18
206	Plasma levels and cerebrospinal fluid penetration by duloxetine in a patient with a non-fatal overdose during a suicide attempt. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 1431.	1.0	18
207	Clozapine Plasma Level Monitoring for Prediction of Rehospitalization Schizophrenic Outpatients. <i>Pharmacopsychiatry</i> , 2011, 44, 55-59.	1.7	18
208	Study protocol of the Diabetes and Depression Study (DAD): a multi-center randomized controlled trial to compare the efficacy of a diabetes-specific cognitive behavioral group therapy versus sertraline in patients with major depression and poorly controlled diabetes mellitus. <i>BMC Psychiatry</i> , 2013, 13, 206.	1.1	18
209	Reduced clearance of venlafaxine in a combined treatment with quetiapine. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2018, 85, 116-121.	2.5	18
210	QTc Time Correlates with Amitriptyline and Venlafaxine Serum Levels in Elderly Psychiatric Inpatients. <i>Pharmacopsychiatry</i> , 2019, 52, 38-43.	1.7	18
211	Effects of short-term exposure to catecholestrogens on catecholamine turnover in the preoptic-hypothalamic brain of ovariectomized rats. <i>Brain Research</i> , 1982, 240, 295-301.	1.1	17
212	Evidence that 3 β -hydroxy-5 β -pregnan-20-one is a physiologically relevant modulator of gaba-ergic neurotransmission. <i>Psychoneuroendocrinology</i> , 1991, 16, 517-523.	1.3	17
213	Non-competitive inhibition of clomipramineN-demethylation by fluvoxamine. <i>Psychopharmacology</i> , 1995, 117, 149-153.	1.5	17
214	What the Clinician Still Has to Be Reminded Of. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 582.	1.0	17
215	Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene. <i>Clinical Biochemistry</i> , 2009, 42, 1282-1290.	0.8	17
216	The use of ziprasidone in clinical practice: Analysis of pharmacokinetic and pharmacodynamic aspects from data of a drug monitoring survey. <i>European Psychiatry</i> , 2009, 24, 143-148.	0.1	17

#	ARTICLE	IF	CITATIONS
217	Low concentration of ziprasidone in human milk: a case report. <i>International Journal of Neuropsychopharmacology</i> , 2009, 12, 437.	1.0	17
218	The "DGPPN-Cohort" a national collaboration initiative by the German Association for Psychiatry and Psychotherapy (DGPPN) for establishing a large-scale cohort of psychiatric patients. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2013, 263, 695-701.	1.8	17
219	Association between haemorrhages and treatment with selective and non-selective serotonergic antidepressants: Possible implications of quantitative signal detection. <i>Psychiatry Research</i> , 2015, 229, 257-263.	1.7	17
220	Tools for optimising pharmacotherapy in psychiatry (therapeutic drug monitoring, molecular brain) <i>Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 Psychiatry</i> , 2021, 22, 561-628.	1.3	17
221	Therapeutic Reference Ranges for Psychotropic Drugs: A Protocol for Systematic Reviews. <i>Frontiers in Psychiatry</i> , 2021, 12, 787043.	1.3	17
222	Day- and nighttime content of monoamines and their metabolites in the pineal gland of rat and hamster. <i>Neuroscience Letters</i> , 1994, 179, 119-122.	1.0	16
223	Automated Determination of Trimipramine and N-Desmethyl-Trimipramine in Human Plasma or Serum by HPLC With On-Line Solid Phase Extraction. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1995, 18, 3495-3505.	0.9	16
224	Molecular cloning of rat G-protein-coupled receptor kinase 6 (GRK6) from brain tissue, and its mRNA expression in different brain regions and peripheral tissues. <i>Molecular Brain Research</i> , 1997, 49, 278-282.	2.5	16
225	Combination treatment with clozapine and paroxetine in schizophrenia: safety and tolerability data from a prospective open clinical trial. <i>European Neuropsychopharmacology</i> , 1998, 8, 315-320.	0.3	16
226	The TPH intron 7 A218C polymorphism and TCI dimension scores in alcohol-dependent patients: hints to nonspecific psychopathology. <i>Addictive Behaviors</i> , 2005, 30, 1135-1143.	1.7	16
227	Prediction of Antidepressant Response to Venlafaxine by a Combination of Early Response Assessment and Therapeutic Drug Monitoring. <i>Pharmacopsychiatry</i> , 2014, 47, 174-179.	1.7	16
228	Antidepressant polypharmacy and the potential of pharmacokinetic interactions: Doxepin but not mirtazapine causes clinically relevant changes in venlafaxine metabolism. <i>Journal of Affective Disorders</i> , 2018, 227, 506-511.	2.0	16
229	Differences in Duloxetine Dosing Strategies in Smoking and Nonsmoking Patients. <i>Journal of Clinical Psychiatry</i> , 2018, 79, .	1.1	16
230	Blood ethanol levels and adenylyl cyclase activity in lymphocytes of alcoholic patients. <i>Biological Psychiatry</i> , 1999, 45, 489-493.	0.7	15
231	Analysis of Multiple Antidepressant and Antipsychotic Drugs Including Active Metabolites in Serum of Psychiatric Patients by LC with Column Switching and Spectrophotometric Detection. <i>Chromatographia</i> , 2009, 69, 821-827.	0.7	15
232	Effects of antipsychotic treatment on psychopathology and motor symptoms. A placebo-controlled study in healthy volunteers. <i>Psychopharmacology</i> , 2011, 218, 733-748.	1.5	15
233	Severe Tremor After Cotrimoxazole-Induced Elevation of Venlafaxine Serum Concentrations in a Patient With Major Depressive Disorder. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 279-282.	1.0	15
234	Prevalence and sort of pharmacokinetic drug-drug interactions in hospitalized psychiatric patients. <i>Journal of Neural Transmission</i> , 2020, 127, 1185-1198.	1.4	15

#	ARTICLE	IF	CITATIONS
235	Potentially inappropriate medication in older psychiatric patients. <i>European Journal of Clinical Pharmacology</i> , 2021, 77, 331-339.	0.8	15
236	Venlafaxine and α -Desmethylvenlafaxine Concentrations in Plasma and Cerebrospinal Fluid. <i>Journal of Clinical Psychiatry</i> , 2015, 76, 25-31.	1.1	15
237	Automated determination of fluvoxamine in plasma by column-switching high-performance liquid chromatography. <i>Clinical Chemistry</i> , 1992, 38, 2082-6.	1.5	15
238	Simultaneous Automated Determination of Catecholamines, Serotonin, and Their Metabolites in Brain Tissue by HPLC and Electrochemical Detection. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1993, 16, 447-463.	0.9	14
239	Serum Levels of Sulpiride Enantiomers after Oral Treatment with Racemic Sulpiride in Psychiatric Patients: a Pilot Study. <i>Pharmacopsychiatry</i> , 2001, 34, 27-32.	1.7	14
240	Spatial Learning and Expression Patterns of PP1 mRNA in Mouse Hippocampus. <i>Neuropsychobiology</i> , 2010, 61, 188-196.	0.9	14
241	Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene. <i>World Journal of Biological Psychiatry</i> , 2010, 11, 382-389.	1.3	14
242	Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine. <i>Clinical Pharmacokinetics</i> , 2018, 57, 729-737.	1.6	14
243	Buprenorphine-cannabis interaction in patients undergoing opioid maintenance therapy. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2020, 271, 847-856.	1.8	14
244	Dose-Related Concentrations of Neuroactive/Psychoactive Drugs Expected in Blood of Children and Adolescents. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 315-324.	1.0	14
245	Therapeutic drug monitoring of antidepressants – clinical aspects. , 2007, , 261-267.		14
246	Preferential uptake of norepinephrine into dopaminergic terminals of a synaptosomal preparation from rat cerebral cortex. <i>Brain Research</i> , 1984, 301, 149-152.	1.1	13
247	Day- and night-time contents of monoamines and their metabolites in the medial preoptic area of the rat hypothalamus. <i>Neuroscience Letters</i> , 1999, 266, 29-32.	1.0	13
248	Behavioral Effects of GABAA Receptor Stimulation and GABA-Transporter Inhibition. <i>Pharmacology Biochemistry and Behavior</i> , 2000, 65, 351-356.	1.3	13
249	“There is no dose-response relationship in psychopharmacotherapy vs pharmacotherapy in psychiatry is based on ligand-receptor interaction”: a unifying hypothesis and the need for plasma concentration based clinical trials. <i>Psychopharmacology</i> , 2011, 217, 297-300.	1.5	13
250	Evaluation of P-glycoprotein (abcb1a/b) modulation of [18F]fallypride in MicroPET imaging studies. <i>Neuropharmacology</i> , 2014, 84, 152-158.	2.0	13
251	hs-CRP Predicts Improvement in Depression in Patients With Type 1 Diabetes and Major Depression Undergoing Depression Treatment: Results From the Diabetes and Depression (DAD) Study. <i>Diabetes Care</i> , 2016, 39, e171-e173.	4.3	13
252	Drug-Induced Liver Injury Associated With Antidepressive Psychopharmacotherapy: An Explorative Assessment Based on Quantitative Signal Detection Using Different MedDRA Terms. <i>Journal of Clinical Pharmacology</i> , 2016, 56, 769-778.	1.0	13

#	ARTICLE	IF	CITATIONS
253	Clinical response in a risperidone-medicated naturalistic sample: patients' characteristics and dose-dependent pharmacokinetic patterns. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2017, 267, 325-333.	1.8	13
254	Body mass index as a determinant of clozapine plasma concentrations: A pharmacokinetic-based hypothesis. <i>Journal of Psychopharmacology</i> , 2021, 35, 273-278.	2.0	13
255	Free-choice ethanol consumption under the influence of GABAergic drugs in rats. <i>Alcoholism: Clinical and Experimental Research</i> , 2002, 26, 457-62.	1.4	13
256	[123I]IBZM SPECT in patients treated with typical and atypical neuroleptics: relationship to drug plasma levels and extrapyramidal side effects. <i>Psychiatry Research - Neuroimaging</i> , 1997, 75, 103-114.	0.9	12
257	Doxepin and its metabolites in plasma and cerebrospinal fluid in depressed patients. <i>Psychopharmacology</i> , 1997, 131, 19-22.	1.5	12
258	Risk of Bleeding Related to Selective and Non-selective Serotonergic Antidepressants: A Case/Non-case Approach Using Data from Two Pharmacovigilance Databases. <i>Pharmacopsychiatry</i> , 2015, 48, 19-24.	1.7	12
259	Measuring citalopram in blood and central nervous system. <i>International Clinical Psychopharmacology</i> , 2016, 31, 119-126.	0.9	12
260	Sex and body weight are major determinants of venlafaxine pharmacokinetics. <i>International Clinical Psychopharmacology</i> , 2018, 33, 322-329.	0.9	12
261	Pharmacodynamic Drug-Drug interactions of QT-prolonging drugs in hospitalized psychiatric patients. <i>Journal of Neural Transmission</i> , 2021, 128, 243-252.	1.4	12
262	Chronical haloperidol and clozapine treatment in rats: Differential RNA display analysis, behavioral studies and serum level determination. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 1998, 22, 1129-1139.	2.5	11
263	Behavioral analysis indicates benzodiazepine-tolerance mediated by the benzodiazepine binding-site at the GABAA-receptor. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2001, 25, 1145-1160.	2.5	11
264	French summaries of product characteristics: content in relation to therapeutic monitoring of psychotropic drugs. <i>Fundamental and Clinical Pharmacology</i> , 2010, 24, 377-384.	1.0	11
265	Behavioural Consequences of Glycoprotein Deficiency in Mice, with Special Focus on Stress-Related Mechanisms. <i>Journal of Neuroendocrinology</i> , 2012, 24, 809-817.	1.2	11
266	Abuse liability of flupirtine revisited: Implications of spontaneous reports of adverse drug reactions. <i>Journal of Clinical Pharmacology</i> , 2013, 53, 1328-1333.	1.0	11
267	Cytochrome P450-mediated interaction between perazine and risperidone: implications for antipsychotic polypharmacy. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 1668-1675.	1.1	11
268	Pharmacotherapy, drug-drug interactions and potentially inappropriate medication in depressive disorders. <i>PLoS ONE</i> , 2021, 16, e0255192.	1.1	11
269	Reboxetine and cytochrome P450 - comparison with paroxetine treatment in humans. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2007, 45, 36-44.	0.3	11
270	Interleukin-6 in plasma collected with an indwelling cannula reflects local, not systemic, concentrations. <i>Clinical Chemistry</i> , 1994, 40, 1778-9.	1.5	11

#	ARTICLE	IF	CITATIONS
271	Do catecholestrogens interact with the in vitro binding of radioligands to catecholamine receptors?. The Journal of Steroid Biochemistry, 1983, 19, 1469-1474.	1.3	10
272	Actions of sex hormones on the brain. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 1992, 16, 377-388.	2.5	10
273	Fluvoxamine Strongly Inhibits Melatonin Metabolism in a Patient With Low-Amplitude Melatonin Profile. Archives of General Psychiatry, 2000, 57, 812.	13.8	10
274	Inhibitory potencies of trimipramine and its main metabolites at human monoamine and organic cation transporters. Psychopharmacology, 2011, 217, 289-295.	1.5	10
275	Pharmacodynamic Effects of Aripiprazole and Ziprasidone with Respect to P-Glycoprotein Substrate Properties. Pharmacopsychiatry, 2013, 46, 175-180.	1.7	10
276	Melperone but not bisoprolol or metoprolol is a clinically relevant inhibitor of CYP2D6: evidence from a therapeutic drug monitoring survey. Journal of Neural Transmission, 2015, 122, 1609-1617.	1.4	10
277	Dopamine D2 Receptor Occupancy Estimated From Plasma Concentrations of Four Different Antipsychotics and the Subjective Experience of Physical and Mental Well-Being in Schizophrenia. Journal of Clinical Psychopharmacology, 2019, 39, 550-560.	0.7	10
278	Predicting the risk of drug-drug interactions in psychiatric hospitals: a retrospective longitudinal pharmacovigilance study. BMJ Open, 2021, 11, e045276.	0.8	10
279	Low novelty seeking and high self directedness scores in alcohol-dependent patients without comorbid psychiatric disorders homozygous for the A10 allele of the dopamine transporter gene. World Journal of Biological Psychiatry, 2010, 11, 1-8.	1.3	10
280	Oxybutynin Enhances the Metabolism of Clomipramine and Dextrophan Possibly by Induction of a Cytochrome P450 Isoenzyme. Journal of Clinical Psychopharmacology, 1999, 19, 287-289.	0.7	10
281	Time-dependent effects of oestradiol and progesterone on hypothalamic catecholamine turnover in ovariectomized rats. Journal of Endocrinology, 1985, 106, 303-309.	1.2	10
282	The action of 5 α -dihydrotestosterone and antiandrogens on the activities of 5 α -reductase and 3 β -hydroxysteroid dehydrogenase in the pituitary gland of gonadectomized rats. The Journal of Steroid Biochemistry, 1982, 16, 545-552.	1.3	9
283	Improved model for the induction of proestrus-like gonadotropin surges in long-term ovariectomized rats. The Journal of Steroid Biochemistry, 1987, 28, 357-359.	1.3	9
284	Formation and metabolism of catecholestrogens in depressed patients. Biological Psychiatry, 1990, 28, 685-696.	0.7	9
285	Determination of naltrexone and 6 β -naltrexol in human blood: comparison of high-performance liquid chromatography with spectrophotometric and tandem-mass-spectrometric detection. Analytical and Bioanalytical Chemistry, 2010, 396, 1249-1257.	1.9	9
286	Severe Adverse Drug Events Under Combination of Nortriptyline and Melperone Due to Pharmacokinetic Interaction. Journal of Clinical Psychopharmacology, 2014, 34, 394-396.	0.7	9
287	Lamotrigine in pregnancy - therapeutic drug monitoring in maternal blood, amniotic fluid, and cord blood. International Clinical Psychopharmacology, 2015, 30, 249-254.	0.9	9
288	Distribution pattern of mirtazapine and normirtazapine in blood and CSF. Psychopharmacology, 2015, 232, 807-813.	1.5	9

#	ARTICLE	IF	CITATIONS
289	Amphiphilic Copolymers Shuttle Drugs Across the Blood–Brain Barrier. <i>Macromolecular Bioscience</i> , 2016, 16, 655-665.	2.1	9
290	Current use of anticholinergic medications in a large naturalistic sample of psychiatric patients. <i>Journal of Neural Transmission</i> , 2021, 128, 263-272.	1.4	9
291	Determination of benperidol and its reduced metabolite in human plasma by high-performance liquid chromatography and electrochemical detection. <i>Biomedical Applications</i> , 1991, 565, 363-373.	1.7	8
292	Quantitation of GABA transporter 3 (GAT3) mRNA in rat brain by competitive RT–PCR. <i>Brain Research Protocols</i> , 1999, 4, 341-350.	1.7	8
293	Induction of Drug Transporters Alters Disposition of Risperidone - A Study in Mice. <i>Pharmaceutics</i> , 2010, 2, 258-274.	2.0	8
294	Cerebrospinal Fluid Tau Protein Levels and ¹⁸ F-Fluorodeoxyglucose Positron Emission Tomography in the Differential Diagnosis of Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 245-253.	0.7	8
295	Quetiapine and Norquetiapine Serum Concentrations and Clinical Effects in Depressed Patients Under Augmentation Therapy With Quetiapine. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 539-545.	1.0	8
296	Influence of Concomitant Medications on the Total Clearance and the Risk for Supra-therapeutic Plasma Concentrations of Citalopram. A Population-Based Cohort Study. <i>Pharmacopsychiatry</i> , 2014, 47, 239-244.	1.7	8
297	Hamilton depression rating subscales to predict antidepressant treatment outcome in the early course of treatment. <i>Journal of Affective Disorders</i> , 2015, 175, 199-208.	2.0	8
298	Duloxetine enters the brain – But why is it not found in the cerebrospinal fluid. <i>Journal of Affective Disorders</i> , 2016, 189, 159-163.	2.0	8
299	Pharmacokinetics of venlafaxine in treatment responders and non-responders: a retrospective analysis of a large naturalistic database. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 1109-1116.	0.8	8
300	Cytochrome P450-mediated inhibition of venlafaxine metabolism by trimipramine. <i>International Clinical Psychopharmacology</i> , 2019, 34, 241-246.	0.9	8
301	Non-adherence to psychotropic medication assessed by plasma level in newly admitted psychiatric patients: Prevalence before acute admission. <i>Psychiatry and Clinical Neurosciences</i> , 2019, 73, 175-178.	1.0	8
302	Pharmacokinetic interactions between clozapine and sertraline in smokers and non-smokers. <i>Basic and Clinical Pharmacology and Toxicology</i> , 2020, 127, 303-308.	1.2	8
303	Tolerability of High-Dose Venlafaxine After Switch From Escitalopram in Nonresponding Patients With Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2021, 41, 62-66.	0.7	8
304	Monitoring tricyclic antidepressant concentrations in serum by fluorescence polarization immunoassay compared with gas chromatography and HPLC. <i>Clinical Chemistry</i> , 1994, 40, 929-33.	1.5	8
305	Is Therapeutic Drug Monitoring Relevant for Antidepressant Drug Therapy? Implications From a Systematic Review and Meta-Analysis With Focus on Moderating Factors. <i>Frontiers in Psychiatry</i> , 2022, 13, 826138.	1.3	8
306	Subcellular Distribution of 3 β -Hydroxysteroid Dehydrogenase and Antiestrogen Action on Androgen-Metabolizing Enzymes in Rat Pituitary Gland. <i>Journal of Neurochemistry</i> , 1982, 38, 876-883.	2.1	7

#	ARTICLE	IF	CITATIONS
307	Production of the Neurosteroid 3alpha-Hydroxy-5alpha-pregnan-20-one in Man. <i>Journal of Neuroendocrinology</i> , 1991, 3, 261-265.	1.2	7
308	New dopamine D2 receptor polymorphisms in rats and association with apomorphine-induced stereotypies. <i>Brain Research</i> , 2002, 926, 1-9.	1.1	7
309	No effect of six weeks of treatment with escitalopram on mood in healthy volunteers " Irrespective of genotype for the promoter of the serotonin transporter. <i>Psychiatry Research</i> , 2008, 161, 339-343.	1.7	7
310	No Influence of Dialysis on Mirtazapine " A Case Report. <i>Pharmacopsychiatry</i> , 2008, 41, 259-260.	1.7	7
311	Retrospective Pilot Study for Analysis of Antidepressant Serum Concentrations of Citalopram and Venlafaxine during Inflammation. <i>Pharmacopsychiatry</i> , 2015, 48, 215-218.	1.7	7
312	Pharmacokinetic considerations in antipsychotic augmentation strategies: How to combine risperidone with low-potency antipsychotics. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2017, 76, 101-106.	2.5	7
313	Interaction of modafinil and clomipramine as comedication in a narcoleptic patient. <i>Clinical Neuropharmacology</i> , 1998, 21, 127-9.	0.2	7
314	Determination of Homovanillic Acid in Human Plasma Using HPLC with Electrochemical Detection and Automated Solid Phase Extraction. <i>Journal of Liquid Chromatography and Related Technologies</i> , 1993, 16, 2813-2823.	0.9	6
315	Pharmacokinetics and bioavailability of benperidol in schizophrenic patients after intravenous and two different kinds of oral application. <i>Psychopharmacology</i> , 1994, 116, 457-463.	1.5	6
316	The neuroendocrinological profile of roxindole, a dopamine autoreceptor agonist, in schizophrenic patients. <i>Psychopharmacology</i> , 1995, 117, 472-478.	1.5	6
317	Diurnal Variations of Plasma Interleukin" in Man: Methodological Implications of Continuous Use of Indwelling Cannulae. <i>Annals of the New York Academy of Sciences</i> , 1995, 762, 468-470.	1.8	6
318	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2012, , 441-464.		6
319	Safety of Psychotropic Medications in People With COVID-19: Evidence Review and Practical Recommendations. <i>Focus (American Psychiatric Publishing)</i> , 2020, 18, 466-481.	0.4	6
320	Amisulpride and olanzapine combination treatment versus each monotherapy in acutely ill patients with schizophrenia in Germany (COMBINE): a double-blind randomised controlled trial. <i>Lancet Psychiatry</i> , 2022, 9, 291-306.	3.7	6
321	Distribution and Properties of Thiol S-Methyltransferase in Rat Brain. <i>Journal of Neurochemistry</i> , 1983, 40, 592-594.	2.1	5
322	Re-establishment of stimulatory estradiol effects on luteinizing hormone secretion in long term ovariectomized rats. <i>Brain Research</i> , 1984, 294, 182-185.	1.1	5
323	Antioestrogen inhibition of oestradiol-induced alterations in hypothalamic noradrenaline turnover. <i>Journal of Endocrinology</i> , 1985, 106, 37-42.	1.2	5
324	Activity of the Adenylyl Cyclase in Lymphocytes of Male Alcoholic Patients Is State Dependent. <i>Alcoholism: Clinical and Experimental Research</i> , 1998, 22, 2073-2079.	1.4	5

#	ARTICLE	IF	CITATIONS
325	Elevated Quetiapine Serum Concentrations in a Patient Treated Concomitantly With Doxepin, Lorazepam, and Pantoprazole. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 568-571.	0.7	5
326	Clinical Relevance of TDM of SSRIs. <i>Therapeutic Drug Monitoring</i> , 2006, 28, 716-717.	1.0	5
327	P-Glycoprotein Influence on the Brain Uptake of a 5-HT _{2A} Ligand: [¹⁸ F]MH.MZ. <i>Neuropsychobiology</i> , 2011, 63, 183-190.	0.9	5
328	Therapeutic Drug Monitoring of Zuclopenthixol in a Double-Blind Placebo-Controlled Discontinuation Study in Adults with Intellectual Disabilities and Aggressive Behaviour. <i>Pharmacopsychiatry</i> , 2014, 47, 29-32.	1.7	5
329	Why do antidepressant therapies have such a poor success rate?. <i>Expert Review of Neurotherapeutics</i> , 2016, 16, 597-599.	1.4	5
330	Drug safety and adverse drug reaction reporting behavior related to outpatient opioid replacement therapy: Results from a survey among physicians. <i>Journal of Substance Abuse Treatment</i> , 2017, 74, 7-15.	1.5	5
331	Pharmacokinetic correlates of venlafaxine: associated adverse reactions. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 851-857.	1.8	5
332	Metamizole but not ibuprofen reduces the plasma concentration of sertraline: Implications for the concurrent treatment of pain and depression/anxiety disorders. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 1111-1119.	1.1	5
333	Lack of Smoking Effects on Pharmacokinetics of Oral Paliperidone-analysis of a Naturalistic Therapeutic Drug Monitoring Sample. <i>Pharmacopsychiatry</i> , 2021, 54, 31-35.	1.7	5
334	ADENYLYL CYCLASE ACTIVITY IS INCREASED IN YOUNGER, BUT DECREASED IN OLDER, ALCOHOLIC PATIENTS AFTER DETOXIFICATION. <i>Alcohol and Alcoholism</i> , 2000, 35, 249-254.	0.9	4
335	Detection of TOAD-64 in adult rat brain as revealed by two-dimensional protein gel electrophoresis followed by MALDI mass spectrometry. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2002, 26, 693-698.	2.5	4
336	Therapeutic Drug Monitoring-Based Clozapine Dosing Recommendations. <i>Therapeutic Drug Monitoring</i> , 2007, 29, 130-131.	1.0	4
337	Flupentixol: relevance of stereoselective therapeutic drug monitoring. <i>Psychopharmacology</i> , 2012, 221, 719-720.	1.5	4
338	Making the Case for 'Power Abuse Disorder' as a Nosologic Entity. <i>Pharmacology</i> , 2017, 100, 50-63.	0.9	4
339	Clinical response in patients treated with once-monthly paliperidone palmitate: analysis of a therapeutic drug monitoring (TDM) database. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 1437-1443.	1.8	4
340	Prevalence and type of potential pharmacokinetic drug-drug interactions in old aged psychiatric patients. <i>Contemporary Behavioral Health Care</i> , 2015, 1, 3-10.	0.0	4
341	Therapeutisches Drug-Monitoring von Antidepressiva. , 2002, , 911-922.		4
342	Plasma levels of benperidol, prolactin, and homovanillic acid after intravenous versus two different kinds of oral application of the neuroleptic in schizophrenic patients. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1994, 102, 326-333.	0.6	3

#	ARTICLE	IF	CITATIONS
343	Excretion of 2- and 3-monomethyl ethers of 2-hydroxyestrogens in healthy male volunteers. <i>European Journal of Endocrinology</i> , 1996, 135, 193-197.	1.9	3
344	Rapid cloning of cDNA ends polymerase chain reaction of G-protein-coupled receptor kinase 6: an improved method to determine 5' and 3'-cDNA ends. <i>Brain Research Protocols</i> , 1999, 3, 242-251.	1.7	3
345	Development of Obsessive-Compulsive Symptoms Following Abrupt Discontinuation of Venlafaxine. <i>Frontiers in Psychiatry</i> , 2020, 11, 32.	1.3	3
346	Risk of Bleeding Associated with Antidepressant Drugs: The Competitive Impact of Antithrombotics in Quantitative Signal Detection. <i>Drugs - Real World Outcomes</i> , 2021, 8, 547-554.	0.7	3
347	Interaktionen von Clozapin mit anderen Psychopharmaka. , 1997, , 39-57.		3
348	Pharmacokinetic drug interactions with oral haloperidol in adults: dose correction factors from a combined weighted analysis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2022, 18, 135-149.	1.5	3
349	Drug Monitoring in Psychiatric Patients: Which Approach is Useful to Improve Psychopharmacotherapy?. <i>Pharmacopsychiatry</i> , 1992, 25, 72-74.	1.7	2
350	High Venlafaxine Serum Levels After Prior Fluoxetine Medication. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 295-297.	0.7	2
351	Consensus guideline for therapeutic drug monitoring in psychiatry (2004): Bibliometric analysis of citations for the period 2004-2011. <i>Nordic Journal of Psychiatry</i> , 2016, 70, 202-207.	0.7	2
352	First-Episode Psychosis Possibly due to Roxithromycin-Related Inhibition of Metabolization of Tetrahydrocannabinol. <i>Journal of Clinical Psychopharmacology</i> , 2017, 37, 369-370.	0.7	2
353	Therapeutic Drug Monitoring of Naltrexone and δ^2 -Naltrexol During Anti-craving Treatment in Alcohol Dependence: Reference Ranges. <i>Alcohol and Alcoholism</i> , 2019, 54, 51-55.	0.9	2
354	The Effects of Co-prescription of Pantoprazole on the Clozapine Metabolism. <i>Pharmacopsychiatry</i> , 2020, 53, 65-70.	1.7	2
355	Interaktionen. , 2010, , 405-423.		2
356	Effects of body weight, smoking status, and sex on plasma concentrations of once-monthly paliperidone palmitate. <i>Expert Review of Clinical Pharmacology</i> , 2022, 15, 243-249.	1.3	2
357	Pharmacokinetic Correlates of Once-Monthly Paliperidone Palmitate-Related Adverse Drug Reactions. <i>Clinical Pharmacokinetics</i> , 2021, 60, 1583-1589.	1.6	1
358	Pharmakokinetik, Pharmakogenetik und therapeutisches Drug Monitoring. , 2008, , 375-397.		1
359	Pharmakokinetik und Arzneimittelinteraktionen. , 2017, , 938-951.		1
360	Influence of the body mass index on serum levels of venlafaxine and its active metabolite O-desmethylvenlafaxine. Analysis of a large therapeutic drug monitoring database. <i>Pharmacopsychiatry</i> , 2013, 46, .	1.7	1

#	ARTICLE	IF	CITATIONS
361	Free-Choice Ethanol Consumption Under the Influence of GABAergic Drugs in Rats. Alcoholism: Clinical and Experimental Research, 2002, 26, 457-462.	1.4	1
362	Relation between leukocyte counts and cortisol secretion in CML patients undergoing combined TNF α /IFN γ therapy. Annals of Hematology, 1992, 65, 116-120.	0.8	0
363	56 INHIBITORY EFFECTS OF FLUVOXAMINE ON THE METABOLISM OF CLOMIPRAMINE IN HUMAN AND RAT LIVER MICROSOMES. Therapeutic Drug Monitoring, 1995, 17, 397.	1.0	0
364	Effects of GABA-transporter (GAT) inhibitors on activity and anxiety in rats. Behavioural Pharmacology, 1997, 8, 662-663.	0.8	0
365	Therapeutisches Drug Monitoring von Antidepressiva und Antipsychotika/Therapeutic monitoring of antidepressant and antipsychotic drugs. Laboratoriums Medizin, 2004, 28, 326-333.	0.1	0
366	B77 CITALOPRAM COUNTERACTS DEPRESSIVE-LIKE SYMPTOMS EVOKED BY CHRONIC SOCIAL STRESS IN RATS. Behavioural Pharmacology, 2005, 16, S90.	0.8	0
367	Determination of Drug Concentrations in Serum and Dopamine Receptor Occupancy in Brain for Optimal Antipsychotic Drug Therapy. European Psychiatry, 2009, 24, .	0.1	0
368	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents in the Drug Prescription Information. International Journal of Knowledge Discovery in Bioinformatics, 2010, 1, 1-11.	0.8	0
369	Liver failure under valproic acid. European Psychiatry, 2011, 26, 1282-1282.	0.1	0
370	Therapeutic Drug Monitoring in Psychiatry. Pharmacopsychiatry, 2011, 44, 193-194.	1.7	0
371	P.2.b.009 Regulation of the astrocytic proteins NDRG2 and GFAP in the rat hippocampus by chronic social stress: no reversal by citalopram. European Neuropsychopharmacology, 2012, 22, S246.	0.3	0
372	Personalised medicine in psychiatry? Yes, but how?. Acta Neuropsychiatrica, 2014, 26, 325-326.	1.0	0
373	Monitoring of Plasma Concentrations of Psychotropic Drugs in Pharmacovigilance. , 2016, , 95-119.		0
374	Drug safety related to agents used for opioid maintenance therapy. European Psychiatry, 2017, 41, s870-s870.	0.1	0
375	Methylphenidate challenge test in adults with attention deficit/hyperactivity disorder (ADHD): Clinical effects and their predictors. Human Psychopharmacology, 2020, 35, e2740.	0.7	0
376	Authors'™ Reply to Suhas et al.: Comment on: "Elevated Clozapine Concentrations in Clozapine-Treated Patients with Hypersalivation" Clinical Pharmacokinetics, 2021, 60, 1077-1079.	1.6	0
377	Kann der pharmakologisch aktive N-demethylierte Metabolit von Clozapin die Blut-Hirn-Schranke durchdringen?. , 2001, , 123-126.		0
378	Auftreten von Nebenwirkungen unter Clozapin-Fluvoxamin-Kombination. , 2001, , 133-138.		0

#	ARTICLE	IF	CITATIONS
379	Serotonin-selektive Antidepressiva(SSRI, DSA). , 2002, , 223-363.		0
380	Therapeutisches Drugmonitoring in der Psychiatrie. , 2016, , 1-15.		0
381	Therapeutisches Drug Monitoring. , 2017, , 187-201.		0
382	Pharmakotherapie bei Alterspatienten. , 2017, , 121-139.		0
383	Therapeutisches Drugmonitoring in der Psychiatrie. , 2017, , 671-684.		0
384	Pharmakokinetik und Arzneimittelinteraktionen. , 2019, , 991-1005.		0
385	10 How valid are therapeutic reference ranges for psychotropic drugs?. , 2020, 53, .		0
386	Adverse Drug Reactions, Intoxications and Interactions of Neuropsychotropic Medications. , 2020, , 1-53.		0
387	Pharmacokinetic and Pharmacodynamic Principles. , 2020, , 1-19.		0
388	SPCCTDM, a Catalogue for Analysis of Therapeutic Drug Monitoring Related Contents. , 0, , 319-328.		0
389	Therapeutisches Drugmonitoring zur Therapieoptimierung. , 2005, , 173-184.		0
390	Pharmakokinetik und Arzneimittelinteraktionen. , 2021, , 905-920.		0
391	Activity of the adenylyl cyclase in lymphocytes of male alcoholic patients is state dependent. Alcoholism: Clinical and Experimental Research, 1998, 22, 2073-9.	1.4	0
392	The interactions between COVID-19 drugs and psychotropic agents. European Psychiatry, 2021, 64, S15-S15.	0.1	0
393	P.0911 Drug monitoring of aripiprazole, dehydroaripiprazole and the active moiety: A systematic review on the therapeutic reference range. European Neuropsychopharmacology, 2021, 53, S670.	0.3	0
394	P.0693 Escitalopram: Drug monitoring for dose titration? Systematic literature review on the therapeutic and the dose-related reference range. European Neuropsychopharmacology, 2021, 53, S507-S508.	0.3	0
395	Therapeutic reference range for aripiprazole revised: A systematic review and combined analysis. Pharmacopsychiatry, 2022, , .	1.7	0
396	How valid are therapeutic reference ranges for psychotropic drugs?. Pharmacopsychiatry, 2022, , .	1.7	0

#	ARTICLE	IF	CITATIONS
397	The therapeutic reference range for olanzapine revised â€“ how to combine old and new findings. Pharmacopsychiatry, 2022, , .	1.7	0
398	Is it Time to Reevaluate the Therapeutic Reference Range for the Antidepressant Drug Venlafaxine?. Pharmacopsychiatry, 2022, , .	1.7	0